Under construction – not a live service
Sign in
Taking people in United StatesNo phase

Preparing Patients with Bladder Cancer for Bladder Removal Surgery

Tests exercise and nutrition support before cystectomy in adults with bladder cancer.

Plain-language title generated from the registry record
Registry title: Patient-Centered Surgical Prehabilitation

Key facts

Where
Boston, United StatesSee the 2 sites

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 85 years old?

Source: NCT05715684, who can take part

Where in United States

  • Brigham and Women's HospitalBoston, United StatesTaking people
  • Dana-Farber Cancer InstituteBoston, United StatesTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Brigham and Women's Hospital
Trial code
NCT05715684
Record updated
30 September 2026
Original description
The purpose of this research is to validate the prehabilitation program which is defined as a set of interventions meant to prepare the body physically and nutritionally for the cystectomy procedure.Read full original descriptionShow less

Patient-Centered Surgical Prehabilitation

The purpose of this research is to validate the prehabilitation program which is defined as a set of interventions meant to prepare the body physically and nutritionally for the cystectomy procedure.

Inclusion: Patents must be candidates for all types of cystectomy surgery including urinary diversion via open or robotic approach; Patients between the ages 18 and 85 years; American Society of Anesthesiologists (ASA) Physical Status Score of class 1-4; Ileal conduit or ileal neobladder urinary diversion; Able to understand the study procedures, agreed to participate in the study program, and voluntarily provided informed consent.

Exclusion: Previous total colectomy, gastrectomy, or gastric bypass, or functional colostomy or ileostomy; More than three doses of opioids (oral or parenteral) within 7 days before the day of surgery; Chemotherapy for bladder cancer within 1 month of scheduled surgery; prior neoadjuvant chemotherapy allowed; Participated in another investigational drug or medical device study within 30 days of surgery or planning to be enrolled in another investigational drug or medical device study or any study in which active patient participation was required outside normal hospital data collection during the course of this study; Using illicit drugs or abusing alcohol; History of previous surgeries, illness, or behavior (eg, depression, psychosis) that in the opinion of the investigator might have confounded the study results or might have posed additional risk in administering the study procedures; The presence of metastatic cancer; Be undergoing treatment for another type of cancer concurrently; Patients with severe dementia (as determined from medical records and history. Severe dementia will be defined as dementia that impacts daily functioning.); Patients with severe hepatic impairment as defined by Child-Pugh Class C. Patients with Child-Pugh Class A-B hepatic impairment are eligible for the study; A history of heart failure; Patients with heart failure; Pregnant (identified by a positive serum pregnancy test administered after the initial screening process and before the commencement of study activities) or lactating, or not postmenopausal (no menses for at least 1 year) and of childbearing potential and not using an accepted method of birth control (i.e, surgical sterilization; intrauterine contraceptive device; oral contraceptive, diaphragm, or condom in combination with contraceptive cream, jelly, or foam; or abstinence) (Participants will be asked to use birth control for the entire study and for at least 2 weeks after the last dose of study drug.); Clinically significant laboratory abnormalities at screening that would have resulted in the cancellation of surgery; Patients with end-stage renal disease as defined by GFR <15; Scheduled for a partial cystectomy; Patients with complete gastrointestinal obstruction; Patients with gastrostomy tube, jejunostomy tube or who require enteral tube feeds; Non-English-speaking patients.

ClinicalTrials.gov NCT05715684